Evidence map›Paper›PMID 39584082›Full record

ArticleHeliyon2024

Perceptual constancy of pareidolias across paper and digital testing formats in neurodegenerative diseases.

Gajanan S Revankar, Tatsuhiko Ozono, Maki Suzuki, Hideki Kanemoto, Kota Furuya, Kazue Shigenobu, Kenji Yoshiyama, Yuki Yamamoto, Issei Ogasawara, Natsuki Yoshida and 18 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Gajanan S RevankarCenter for Global Health, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Tatsuhiko OzonoDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Maki SuzukiDepartment of Behavioral Neurology and Neuropsychiatry, United Graduate School of Child Development, Osaka University, Osaka, Japan.
Hideki KanemotoDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Osaka, Japan.
Kota FuruyaCenter for Global Health, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Kazue ShigenobuDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Osaka, Japan.
Kenji YoshiyamaDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuki YamamotoDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Osaka, Japan.
Issei OgasawaraDepartment of Health and Sport Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Natsuki YoshidaDepartment of Health and Sport Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Susumu IwasakiDepartment of Health and Sport Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Chizu SaekiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yoshiyuki NishioDepartment of Behavioral Neurology and Neuropsychiatry, United Graduate School of Child Development, Osaka University, Osaka, Japan.
Daisaku NakataniCenter for Global Health, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Kanako AsaiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuta KajiyamaDepartment of Neurology, Kawasaki Medical School, Okayama, Japan.
Mikito ShimizuDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tatsuya HayashiDepartment of Health and Sport Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Seira TaniguchiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yu SuzukiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Rino InadaDepartment of Neurology, Kindai University Faculty of Medicine, Osaka, Japan.
Tomoya TaminatoDepartment of Neurology, Kindai University Faculty of Medicine, Osaka, Japan.
Yoshitaka NagaiDepartment of Neurology, Kindai University Faculty of Medicine, Osaka, Japan.
Mamoru HashimotoDepartment of Psychiatry, Kindai University Faculty of Medicine, Osaka, Japan.
Manabu IkedaDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Osaka, Japan.
Etsuro MoriDepartment of Behavioral Neurology and Neuropsychiatry, United Graduate School of Child Development, Osaka University, Osaka, Japan.
Hideki MochizukiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Ken NakataCenter for Global Health, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pareidolias refer to visual perceptual deficits where ambiguous shapes take on meaningful appearances. In neurodegenerative diseases, pareidolias are examined via a paper-based neuropsychological tool called the noise pareidolia test. In this study, we present initial findings regarding the utilization of pareidolia test on a digital format to analyze variations between paper-based and digital testing approaches. We performed our experiments on healthy controls, patients diagnosed with Alzheimer's disease (AD), Dementia with Lewy body disease (DLB) and Parkinson's disease (PD). Baseline MMSE assessments were conducted, followed by pareidolia testing using both paper-based tools and smartphones. Bland-Altman analysis was performed to evaluate the agreement between the two methods. We found that the illusionary phenomenon of pareidolia is consistent across paper and digital modalities of testing; that perceptual constancy is maintained across patient groups despite variations in image sizes; and pareidolic misperceptions, to some extent, are stabilized on a digital format. Our findings demonstrate a practical way of testing pareidolias on smartphones without compromising on the functionality of the test.

Indexed as

Alzheimer's diseaseDementia with lewy bodymHealthNeurodegenerative diseasesPareidoliaVisual perception

Identifiers

PMID39584082
PMCPMC11585718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.